Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
Resistant Hypertension
About this trial
This is an interventional treatment trial for Resistant Hypertension focused on measuring Resistant hypertension, ambulatory blood pressure, sacubitril/valsartan, valsartan
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of resistant hypertension
- ≥18 and ≤75 years old at the time of randomization
- Must agree to comply with all requirements and sign the informed consent form
Exclusion Criteria:
- unwilling to sign informed consent.
- Severe renal insufficiency
- Research related drug contraindications
- secondary hypertension
- Cardiovascular event
- Persistent arrhythmia, valvular heart disease, and class III-IV heart failure or left ventricular ejection fraction <45%.
- Severe liver function impairment (Child-Pugh C), biliary cirrhosis and/or cholestasis
- History of angioedema and asthma
- Woman of childbearing age who do not take effective contraceptive measures or pregnant or breastfeeding
- Allergic to drugs related to the study
- Suffering from serious tumor-related diseases, receives tumor-related treatment, or has a life expectancy of less than 2 years
- Planning to join other clinical trials
- Anticipated changes in medical conditions
- Need to take study-related drugs for reasons other than hypertension
- Suffering from other diseases that may prevent the patient from participating fully period of the study
- Other any concomitant conditions
- Must continuously take any drugs that affect the results
Sites / Locations
- Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
sacubitril/valsartan group
valsartan group
The experimental group will be sacubitril/valsartan group. Patients assigned to this group will receive sacubitril/valsartan 200mg added to existing medication regimens before randomization including amlodipine 10mg per day, hydrochlorothiazide 25 mg per day, spironolactone 20 mg per day. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
The control group will be valsartan group, which patients will receive valsartan 160mg added to existing medication regimens before randomization including amlodipine 10mg per day, hydrochlorothiazide 25 mg per day, spironolactone 20 mg per day. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.